TB-500 & thymosin β4 – Learning Health

What it is

Two molecules get discussed as if they were one, and almost every confusion about this compound comes from that conflation.

Thymosin β4 (Tβ4) is a real, naturally occurring 43-residue protein. It is one of the most abundant actin-sequestering proteins in cells, it is released by platelets and macrophages at the site of an injury, and it is an early participant in the repair cascade. It has been developed as an actual drug candidate and has been through controlled clinical trials.

TB-500 is not that. When a doping-control laboratory analysed a product sold as TB-500 by high-resolution mass spectrometry, what it contained was the N-terminally acetylated 17–23 fragment of human thymosin β4 — Ac-LKKTETQ, seven residues. That short stretch includes the actin-binding motif, which is the rationale for selling it, but it is roughly a sixth of the protein and it has never been tested in a human trial.

What it does in the body

Full-length Tβ4 binds actin and promotes cell migration, including the mobilisation and differentiation of stem and progenitor cells that build new blood vessels. It reduces apoptosis and inflammation, and in wound models it decreases the number of myofibroblasts, which is the proposed basis for less scarring and less fibrosis. In mouse hearts, Tβ4 mobilised adult epicardial progenitor cells and promoted neovascularisation — a finding that drove a decade of cardiac-repair interest.

In animal wound models the effect is broad and reproducible: Tβ4 accelerated healing of full-thickness punch wounds in normal rats and mice, steroid-treated rats, diabetic mice and aged mice.

What the human evidence shows

All of it is on full-length Tβ4, and nearly all of it is topical or ophthalmic rather than injected.

Chronic skin ulcers. In two phase 2 trials in stasis and pressure ulcers, Tβ4 accelerated healing by close to a month — but only in the subset of patients who healed at all.
Dry eye (phase 2). Seventy-two patients randomised 1:1 to 0.1% Tβ4 eye drops or placebo for 28 days. Neither primary endpoint was met — not ocular discomfort, not inferior corneal staining. Several secondary endpoints did reach significance: discomfort during an environmental challenge was 27% lower (p=0.024), and central and superior corneal staining improved (p=0.008 and p=0.021).
Neurotrophic keratopathy (phase 3). A small randomised, placebo-controlled, double-masked trial: complete healing of persistent epithelial defects at four weeks in 6 of 10 treated versus 1 of 8 on placebo (p=0.066 — a trend, not significance, in a trial this size). Disease stage improved at day 43 (p=0.047), the one healed placebo patient relapsed, and no significant adverse effects were seen.

So: a credible drug candidate with real but mixed trial results in eye and skin surface indications. There is no published controlled trial of injected Tβ4 — and none at all of the TB-500 fragment — for tendon, muscle or joint repair in humans, which is what it is overwhelmingly marketed for.

Claims and what backs them

Claim as usually stated	Verdict	What the published evidence actually shows
Repairs tendons, muscles and ligaments in humans	Unproven	No human trial exists for this use, for either molecule. The claim is extrapolated from rodent wound-healing models and from the actin-binding mechanism.
Speeds healing of chronic wounds	Mixed	Two phase 2 trials in stasis and pressure ulcers found healing accelerated by nearly a month — among patients who healed. That is a real signal in a hard indication, on full-length Tβ4, applied topically.
Helps the ocular surface heal	Mixed	The strongest human data in the whole file. A phase 3 trial in neurotrophic keratopathy favoured Tβ4 drops on several measures; the phase 2 dry-eye trial missed both primary endpoints while hitting secondaries.
Reduces scarring and fibrosis	Unproven	Mechanistically plausible — Tβ4 reduces myofibroblast numbers in animal wounds — but not demonstrated as a clinical endpoint in people.
TB-500 is just thymosin β4	Not supported	Mass-spectrometry analysis of the product identified a seven-residue acetylated fragment, Ac-LKKTETQ. Trials of the 43-residue protein do not transfer to it.

Risks and unknowns

The tumour-biology problem is specific, not hand-waving. Thymosin β4 is upregulated in a wide range of human carcinomas. In colorectal cancer, forced Tβ4 expression in SW480 cells markedly increased invasiveness along with matrix metalloproteinase-7 activity, decreased Fas levels and reduced susceptibility to Fas-ligand-mediated apoptosis; in matched patient samples, Tβ4 messenger RNA was higher in liver metastases than in the primary tumour. The authors proposed Tβ4 upregulation as a key event in acquiring an invasive phenotype. A healthy person injecting a fragment designed to mimic that protein is acting against this literature, not alongside it.

The fragment is uncharacterised in people. No pharmacokinetics, no dose-finding, no safety database. When FDA staff reviewed it for the compounding list, the objection raised was that its form was unknown — one official asked how a substance could be listed when it is not clear what it is.

Grey-market supply. Thymosin β4 has turned up in confiscated black-market products analysed by a doping-control laboratory, alongside steroids and growth-hormone-releasing peptides, in a sample set that also contained fake and non-approved material.

Where regulators stand

United StatesNeither Tβ4 nor TB-500 is an approved drug. “Thymosin beta-4 fragment (LKKTETQ), also known as TB-500” appears in the FDA’s table of bulk substances previously in Category 2 whose nominations were withdrawn by the nominators.

The July 2026 voteOn 23–24 July 2026 the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides for possible addition to the 503A bulks list. The agency’s own scientific staff recommended against all seven, citing thin clinical data, inconsistent manufacturing and the basic problem of chemical identity. The committee voted in favour of six of them anyway, by narrow margins. TB-500 acetate was voted through 8–6 with one abstention, with wound healing as the indication under review. It remains a recommendation only; no rule has been issued.

SportProhibited at all times. The WADA 2026 Prohibited List names “Thymosin-ß4 and its derivatives e.g. TB-500” under S2.3 — Growth Factors and Growth Factor Modulators, alongside IGF-1, VEGF, FGFs, HGF, PDGF and mechano growth factors. Note that this entry explicitly covers derivatives, so the fragment is caught as squarely as the protein. Doping-control assays for TB-500 in plasma and urine have been published since 2012.

Ophthalmic developmentTβ4 eye drops have been developed under the name RGN-259 and have reached phase 3 for neurotrophic keratopathy. That is a different product, route and indication from anything sold as TB-500.

The bottom line

Thymosin β4 is a legitimate research molecule with a plausible biology and modest, mixed clinical results in surface tissues — eyes and skin — where it can be applied directly. TB-500 is a short fragment of it, sold for injection, tested in nobody.

Anyone citing “clinical trials of TB-500” is citing trials of a different molecule, in a different formulation, for a different indication. And the one well-replicated fact about the parent protein in human tissue is that cancers express more of it when they become invasive.

References

Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733–738 PMID 22962027
Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012;12(1):37–51 PMID 22074294
Treadwell T, Kleinman HK, Crockford D, et al. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci. 2012;1270:37–44 PMID 23050815
Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial. Clin Ophthalmol. 2015;9:877–884 PMID 26056426
Sosne G, Kleinman HK, Springs C, et al. 0.1% RGN-259 (thymosin ß4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked phase III clinical trial. Int J Mol Sci. 2022;24(1):554 PMID 36613994
Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177–182 PMID 17108969
Wang WS, Chen PM, Hsiao HL, et al. Overexpression of the thymosin beta-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma. Oncogene. 2004;23(39):6666–6671 PMID 15235586
Krug O, Thomas A, Walpurgis K, et al. Identification of black market products and potential doping agents in Germany 2010–2013. Eur J Clin Pharmacol. 2014;70(11):1303–1311 PMID 25168622
World Anti-Doping Agency. The 2026 Prohibited List, International Standard. In force 1 January 2026 — class S2.3 Source